2003
Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States)
Li L, Yu H, Schumacher F, Casey G, Witte J. Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes & Control 2003, 14: 721-726. PMID: 14674736, DOI: 10.1023/a:1026383824791.Peer-Reviewed Original ResearchConceptsIGFBP-3 molar ratioInsulin-like growth factorIGFBP-3Prostate cancerHigher IGFOdds ratioSibling-matched case-control studySerum insulin-like growth factorInsulin-like growth factor IProtein 3Growth factorIGFBP-3 associationSerum IGF levelsEffects of IGFConfidence intervalsImportant risk factorCase-control studyConditional logistic regressionGrowth factor IProstatic epithelial cellsAdvanced diseaseSerum IGFIGF levelsAggressive diseaseRisk factors
1995
Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer.
Yu H, Giai M, Diamandis E, Katsaros D, Sutherland D, Levesque M, Roagna R, Ponzone R, Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Research 1995, 55: 2104-10. PMID: 7538047.Peer-Reviewed Original ResearchConceptsProstate-specific antigenIR-PSABreast cancerCox proportional hazards regression modelEstrogen receptor-negative patientsEstrogen receptor-positive tumorsProportional hazards regression modelsIndependent favorable prognostic markerReceptor-negative patientsNode-positive patientsFavorable prognostic indicatorSurvival of patientsReceptor-positive tumorsRelapse-free survivalBreast cancer patientsFemale breast cancerHazards regression modelsEarly disease stagesFavorable prognostic markerProstatic epithelial cellsPSA statusBetter prognosisPositive tumorsPrognostic valueDisease stage